181 results on '"Shihab, F."'
Search Results
2. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data
3. New-Onset Diabetes After Transplantation:Results From a Double-Blind Early Corticosteroid Withdrawal Trial
4. First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection
5. Light Chain Podocytopathy Mimicking Recurrent Focal Segmental Glomerulosclerosis
6. New-Onset Diabetes After Transplantation: Results From a Double-Blind Early Corticosteroid Withdrawal Trial
7. Transfer of peanut IgE sensitisation after combined pancreas–kidney transplant
8. Half-Dose Valcyte for 1 Month in CMV Intermediate Risk Kidney Transplant Recipients… A Cost-Effective Alternative?: Abstract# D2375
9. Three Doses of Thymoglobulin in Kidney Transplant Recipients…a Cost-Effective Alternative?: Abstract# C1807
10. 0% PRA Kidney Transplant Recipients Induced With Thymoglobulin: Is a Dual Maintenance Regimen More Effecitve Than Triple?: Abstract# B991
11. Management of the Wound Complications in De Novo Renal Transplant Recipients: US92 12-Month Randomized Study.: Abstract# B975
12. Influence of Induction Therapy On the Efficacy of Everolimus vs Mycophenolate Based Regimen in De Novo Renal Transplant Recipients.: Abstract# B966
13. Reduced Incidence of CMV and BK Virus Infection With Everolimus vs Mycophenolate Based Regimen in De Novo Renal Transplant Recipients.: Abstract# B959
14. Everolimus-Facilitated Tacrolimus Minimization Preserves Renal Function in De Novo Renal Transplant Recipients.: Abstract# B962
15. Effect of Everolimus With Low Dose Tacrolimus Vs Mycophenolate With Standard Tacrolimus Regimen in African-American De Novo Renal Transplant Recipients.: Abstract# B955
16. Initial Phase 2 Safety, Efficacy, and Pharmacokinetic Study of TOL-101 for Induction Therapy in Kidney Transplantation.: Abstract# 1363
17. Efficacy and Safety of Everolimus With Low-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Randomized Study.: Abstract# 713
18. Effect of Corticosteroid Withdrawal on Tacrolimus and Mycophenolate Mofetil Exposure in a Randomized Multicenter Study
19. Three-Year Comparisons of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry.: Abstract# 1286: Poster Board #-Session: P153-III
20. Exposure-Response Analysis of Everolimus with Reduced Cyclosporine in Renal Transplant Recipients at 24 Months in a Randomized Trial.: Abstract# 929 Poster Board #-Session: P94-II
21. Two-Year Outcomes of African American (AA) Renal Transplant Recipients from the Mycophenolic Acid Observational Renal Transplant (MORE) Registry.: Abstract# 721 Poster Board #-Session: P189-I
22. TOL101- Anti-αβTCR Monoclonal Antibody Immune Monitoring during Initial Phase 2 Renal Transplant Trials.: Abstract# 192
23. First in Man Evaluation of the Safety and Potential Efficacy of TOL101 Induction To Prevent Kidney Transplant Rejection.: Abstract# 99
24. Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials
25. CYTOMEGALOVIRUS AND BK VIRUS INFECTIONS ARE LESS FREQUENT WITH EVEROLIMUS VERSUS MYCOPHENOLATE IMMUNOSUPPRESSION: 24-MONTH UPDATE FROM THE 2309 STUDY IN DE NOVO RENAL TRANSPLANT RECIPIENTS: O-147
26. Successful Treatment of Recurrent Henoch–Schönlein Purpura in a Renal Allograft with Plasmapheresis
27. A Retrospective Analysis of Ezetimibe Treatment in Renal Transplant Recipients
28. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient
29. Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses
30. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation
31. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation
32. Exposure-Response Analysis of Everolimus with Reduced Cyclosporine in Renal Transplant Recipients at 24 Months in a Randomized Trial
33. Influence of Induction Therapy On the Efficacy of Everolimus vs Mycophenolate Based Regimen in De Novo Renal Transplant Recipients.
34. Half-Dose Valcyte for 1 Month in CMV Intermediate Risk Kidney Transplant Recipients… A Cost-Effective Alternative?
35. Initial Phase 2 Safety, Efficacy, and Pharmacokinetic Study of TOL-101 for Induction Therapy in Kidney Transplantation.
36. 0% PRA Kidney Transplant Recipients Induced With Thymoglobulin: Is a Dual Maintenance Regimen More Effecitve Than Triple?
37. Reduced Incidence of CMV and BK Virus Infection With Everolimus vs Mycophenolate Based Regimen in De Novo Renal Transplant Recipients.
38. Three Doses of Thymoglobulin in Kidney Transplant Recipients…a Cost-Effective Alternative?
39. Efficacy and Safety of Everolimus With Low-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Randomized Study.
40. Management of the Wound Complications in De Novo Renal Transplant Recipients: US92 12-Month Randomized Study.
41. Effect of Everolimus With Low Dose Tacrolimus Vs Mycophenolate With Standard Tacrolimus Regimen in African-American De Novo Renal Transplant Recipients.
42. Everolimus-Facilitated Tacrolimus Minimization Preserves Renal Function in De Novo Renal Transplant Recipients.
43. First in Man Evaluation of the Safety and Potential Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection
44. TOL101- Anti-αβTCR Monoclonal Antibody Immune Monitoring During Initial Phase 2 Renal Transplant Trials
45. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De NovoRenal Transplant Recipients: 12-Month Data
46. DE NOVO EVEROLIMUS COMBINED WITH REDUCED CYCLOSPORINE EXPOSURE - ANALYSIS OF RENAL FUNCTION AT 12 MONTHS IN RENAL TRANSPLANT RECIPIENTS
47. EARLY MYCOPHENOLIC ACID (MPA) DOSE MODIFICATIONS ARE ASSOCIATED WITH COMPROMISED GRAFT OUTCOMES: RATIONALE FOR DOSE CHANGES AND ANALYSIS OF EFFECTS IN THE MYCOPHENOLIC ACID OBSERVATIONAL RENAL TRANSPLANT (MORE) REGISTRY
48. A population-based assessment of the familial component of acute kidney allograft rejection
49. A Case of Native Cytomegalovirus Pancreatitis Following Deceased-Donor Renal Transplantation
50. The association between recipient alcohol dependency and long-term graft and recipient survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.